Can circulating tumor DNA be used for direct and early stage cancer detection? [version 1; referees: 2 approved]
In the August 16th issue of Science Translational Medicine, Phallen et al propose a method for early cancer diagnosis by using circulating tumor DNA (1). One major advance of this paper includes optimized sequencing of cell-free/circulating tumor DNA (ctDNA) without knowledge of tumor mutations. Evaluation of 200 patients with colorectal, breast, lung and ovarian cancer revealed mutations in ctDNA in approx. 60-70% of all patients, including stage 1 and stage 2 disease. If this data can be reproduced in asymptomatic individuals, they will likely have a major impact on early cancer detection and patient outcomes. In this commentary, we examine the feasibility of this approach for detecting small, asymptomatic tumors, based on previously published empirical data..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
F1000Research - 6(2017) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eleftherios P Diamandis [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Cancer Therapeutics |
|---|
| doi: |
10.12688/f1000research.13440.1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ065938127 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ065938127 | ||
| 003 | DE-627 | ||
| 005 | 20230502082419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12688/f1000research.13440.1 |2 doi | |
| 035 | |a (DE-627)DOAJ065938127 | ||
| 035 | |a (DE-599)DOAJd9c521aa71c14d1d8c860288710a987c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Eleftherios P Diamandis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Can circulating tumor DNA be used for direct and early stage cancer detection? [version 1; referees: 2 approved] |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In the August 16th issue of Science Translational Medicine, Phallen et al propose a method for early cancer diagnosis by using circulating tumor DNA (1). One major advance of this paper includes optimized sequencing of cell-free/circulating tumor DNA (ctDNA) without knowledge of tumor mutations. Evaluation of 200 patients with colorectal, breast, lung and ovarian cancer revealed mutations in ctDNA in approx. 60-70% of all patients, including stage 1 and stage 2 disease. If this data can be reproduced in asymptomatic individuals, they will likely have a major impact on early cancer detection and patient outcomes. In this commentary, we examine the feasibility of this approach for detecting small, asymptomatic tumors, based on previously published empirical data. | ||
| 650 | 4 | |a Cancer Therapeutics | |
| 650 | 4 | |a Hematological Disorders | |
| 650 | 4 | |a Small Molecule Chemistry | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Clare Fiala |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t F1000Research |d F1000 Research Ltd, 2013 |g 6(2017) |w (DE-627)DOAJ000112240 |x 20461402 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2017 |
| 856 | 4 | 0 | |u https://doi.org/10.12688/f1000research.13440.1 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d9c521aa71c14d1d8c860288710a987c |z kostenfrei |
| 856 | 4 | 0 | |u https://f1000research.com/articles/6-2129/v1 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2046-1402 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2017 | ||